Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix is viewed favorably because AXPAXLI now appears to be the only remaining sustained-release maintenance therapy for wet AMD, after EyePoint’s LUCIA miss and discontinuation of its wAMD program narrowed the competitive field. Management says it is on track for a 4Q26 NDA submission under the single-trial 505(b)(2) pathway, is “absolutely in lockstep” with FDA, expects no AdCom, and has runway into 2028, while SOL-1’s p-value of 0.0006 supports robustness. Fundamentally, the company’s hydrogel platform and continuous VEGF suppression could offer differentiated durability, with modeled AXPAXLI value of $18.16/sh in wAMD and $2.30/sh in NPDR at 75% and 55% POS, respectively.

Ocular Therapeutix is highly dependent on Axpaxli, and any clinical setback in Phase 3 or failure to secure FDA approval after the positive Phase 3 SOL-1 data would sharply weaken the company’s core investment case. The business also faces meaningful commercialization, reimbursement, and competitive pressure, especially against established anti-VEGF therapies from better-resourced large pharmaceutical companies, while patent uncertainty adds another layer of risk. Financially, the company has incurred significant losses since inception, has only one revenue-generating product, and will likely need substantial additional capital to fund development, commercialization, and further indications.